Cardioaortic brain embolism is a potentially devastating condition that presents frequent diagnostic and therapeutic challenges. In this report, we review key aspects of the etiology, clinical presentation, diagnosis, prognosis, and treatment of cardiogenic and aortogenic stroke. Emphasis is on advances in diagnostic imaging capabilities and on recent literature addressing secondary prevention for specific cardioembolic sources, upon which diagnosis and prognosis primarily depend. While early evaluation with modern neuroimaging techniques offers to enhance diagnostic accuracy, additional study is required to define optimal utilization. Appropriate imaging of the heart and aorta is paramount to identifying potential sources of embolism. Secondary prevention for highrisk embolic sources generally involves anticoagulation, but immediate initiation of anticoagulation is not routinely indicated. Medium-risk sources have more modest or undefined risks and little randomized comparative evidence to guide management, but antiplatelet therapy is generally favored. One possible exception is patent foramen ovale, for which high-risk features may warrant anticoagulation or mechanical closure. Definitive recommendations for this and other findings await completion of ongoing clinical trials. (J Am Coll Cardiol 2008; 51:1049-59)
Stroke, which is almost 90% ischemic in nature, is a leading cause of mortality and long-term disability worldwide (1) . While the etiology of ischemic stroke is often found in the cervicocranial vasculature, approximately 20% result from high-risk cardiac abnormalities (2, 3) . In another 30%, the etiology cannot be established (2), but most "cryptogenic" ischemic strokes have embolic features (4) , suggesting a possible cardioaortic origin (3) .
Given the clinical importance of brain embolism arising from the heart and aorta, we prepared a narrative review detailing optimal approaches to diagnosis and secondary prevention based on the latest available evidence and published guidelines.
Pathophysiology
The brain, which receives 15% of cardiac output, is exquisitely sensitive to ischemia. Thus, material dislodged proximally to the great vessels often travels to the cervicocephalic arteries, where impaction tends to manifest in stark clinical terms. Most commonly, the embolic material is thrombus (5), whose propensity for spontaneous dissolution heightens the risk of hemorrhagic conversion (6) . While thromboemboli of central origin frequently occlude cerebral artery stems or major branches (5) , microemboli, such as air, fat, and cholesterol crystals, may travel to smaller terminal branches, leading to watershed infarction (7) .
Symptoms and Signs
Clinical presentation is imperfect in differentiating cardioembolic from noncardioembolic stroke (8) . Cardiogenic brain embolism presents characteristically with neurologic deficits that are maximal at onset, reflecting sudden interruption of blood flow (8) . This contrasts with the stuttering course attributed to atherothrombotic stroke (9) . Yet because emboli can shift or fragment after initial impaction (3), presentation is nonabrupt in at least one-fifth of cardioembolic strokes (8, 9) . Moreover, large-artery atherothrombosis causes not only hypoperfusion (7) , but also artery-to-artery embolism (3) . Accordingly, cardioembolic features can occur in more than two-fifths of noncardioembolic strokes (9) . Particular neurologic deficits favoring a cardioembolic etiology have been identified, but have suboptimal discriminatory capacity (10) . While insensitive, the most specific features for cardioembolism are infarcts in multiple territories and concurrent systemic embolism (8, 10) .
Diagnosis
Diagnosis of cardio/aortogenic infarction depends on circumstantial evidence provided by detection of proximal emboligenic findings (hereafter "cardiac sources of embolism" [CSEs]) (Table 1) and supportive clinical, neuroimaging, or laboratory features.
Neuroimaging. Magnetic resonance imaging (MRI) affords superior resolution than computed tomography (CT), along with the capacity to detect cerebral ischemia within minutes of onset (11) . Cardiac emboli often occlude large arteries or multiple vascular territories (12) , more commonly affect certain vessels (10) , and frequently lead to hemorrhagic transformation (6) . But the utility of infarct features for making a diagnosis of cardioembolism is limited (10) .
Noninvasive vascular imaging has largely supplanted conventional angiography, and can help impugn a cardioaortic source, especially when used early (13) . The finding of a hyperdense cerebral artery by noncontrast CT (14) , denoting thrombus ( Fig. 1) , or its hyperintense counterpart by MRI (15) , confirms the diagnosis in the absence of proximal arterial pathology. Early use of thin-section noncontrast CT in acute stroke outperforms conventional sectioning, identifying intracranial thrombi in almost 90% of cases (16) . The presence of intracranial thrombus may also be detected noninvasively with MRI angiography (17) , CT angiography (18) , or transcranial Doppler (19) . Lately, MRI has been applied to identify erythrocyte-rich thrombi, whose detection provides direct support for cardioembolism (20) .
There are no published guidelines regarding the optimal neuroimaging approach, but contemporary techniques promise substantial improvement in diagnostic accuracy. Ultimately, however, the diagnosis of cardio/aortogenic stroke rests with detection of the embolic source itself, which requires electrocardiographic monitoring and cardioaortic imaging. Echocardiography. In patients with clinically apparent heart disease, the yield for CSEs of conventional transthoracic echocardiography (TTE) with agitated-saline injection may exceed 25% (21) , but falls below 10% otherwise (13) . By contrast, the superior image resolution of transesophageal echocardiography (TEE) permits identification of possible CSEs in more than 50% of patients without clinically overt heart disease (21) or otherwise unexplained cerebrovascular events (22) . In particular, TEE allows the diagnosis of "complex" aortic atheroma (CAA), consisting of protruding, mobile, or ulcerated plaque (23) . Newer techniques, however, have brought the diagnostic accuracy of TTE for right-to-left interatrial shunts closer to TEE (24 -26) . Second-harmonic TTE can attain sensitivities of 62.5% to 90% compared with TEE (24, 25) .
There are scant data regarding the optimal echocardiographic approach in suspected cardioembolic stroke. In a study of unexplained stroke evaluated by both TTE and TEE, the latter technique yielded findings (patent foramen ovale [PFO], aortic thrombus) that prompted a change from antiplatelet to anticoagulant therapy in 30% of cases (27) . Therapeutic decisions were based on clinical judgment, however, and randomized data supporting anticoagulant therapy for these findings are lacking. Published guidelines reflect the shortfall in available evidence and, while acknowledging the superiority of TEE for detecting selected CSEs (Table 2 ) (28), do not make specific recommendations regarding imaging strategy (28, 29) .
Ongoing uncertainties notwithstanding, the higher yield of TTE in patients with clinically overt heart disease supports its use as the initial imaging technique in this setting. Contrariwise, the higher prevalence of potential CSEs that are difficult to detect by TTE in younger patients with unexplained stroke, together with the potentially serious consequences of occult pathology in this population, makes TEE the modality of choice. Although transcranial Doppler with contrast injection can offer comparable diagnostic accuracy to TEE for right-to-left shunts (30) , it cannot provide direct information on cardiac structure.
The case for cardioaortic embolism depends chiefly on detection of a presumptive proximal culprit. Absent 
Prognosis and Treatment
Cardioembolic stroke is associated with a worse outcome than other stroke subtypes (31) . Clinical trials of acute cardioembolic stroke have failed to demonstrate the benefit of acute intravenous anticoagulation, while showing greater symptomatic intracranial hemorrhage compared with antiplatelet therapy (32) . Current guidelines (2,33) do not recommend routine immediate anticoagulation, but favor early antiplatelet treatment for cardioembolic stroke.
In acute as in chronic management, choice of an antithrombotic agent depends on the balance between thromboembolic and hemorrhagic risk. Incidence of hemorrhagic transformation for cardioembolic stroke, ranging from petechiae to intrainfarct hematoma, averages 42% (6) . Peak onset is 2 to 4 days, leading to the proposition that, for atrial fibrillation (AF), anticoagulation should be started 4 days post-stroke (34) . Long-term anticoagulation doubles the risk of intracranial hemorrhage (from 0.3% to 0.6% annually) compared with antiplatelet treatment (35) . Whereas acute hemorrhagic risk correlates with infarct size (6), both acute and chronic risks are determined by age, blood pressure, and intensity and stability of anticoagulation (35) .
Although thromboembolic risk varies with emboligenic substrate, existing literature addressing the risk of individual CSEs is predominantly observational and subject to bias (36) . Nevertheless, available data permit useful categorization of proximal sources based on their known propensity for embolism (Table 1 ). Published treatment guidelines by professional societies center on individual cardioembolic findings (Table 3 ), but the paucity of existing randomized data is an acknowledged limitation. High-risk sources. ATRIAL DYSRHYTHMIAS. Atrial fibrillation is the most common cause of cardioembolic stroke, and its close link to age augurs marked increases in prevalence in coming decades (37, 38) . Valvular AF is associated with higher stroke risk than nonvalvular AF (37) . Thromboembolic risk is similar for paroxysmal and persistent nonvalvular AF, but is strongly determined by associated cardiovascular risk factors (37) . The severity and duration of these risk factors, through their effects on left ventricular (LV) function, influence the extent of left atrial enlargement and, consequently, the likelihood of AF-associated thrombus formation (38) . They also foster aortic and carotid atherosclerosis and small-vessel disease, which along with structural heart disease can themselves cause cerebral ischemia in AF patients (37) . In this context, the interplay of atherosclerotic, inflammatory, and prothrombotic factors has received attention (38) . Risk stratification can be accomplished with clinical prediction instruments such as CHADS 2 , which assigns 1 point each for Congestive heart failure, Hypertension, Age Ͼ75 years, and Diabetes, and 2 points for prior Stroke or transient ischemic attack (39) . While identification of dense smoke or CAA by TEE also predicts AF-associated thromboembolic risk, its additive prognostic value to clinical measures requires further investigation (23) .
Comparison of TTE and TEE for Detection of Specific Cardioaortic Sources of Embolism
Atrial flutter and sick sinus syndrome are often associated with AF and structural heart disease (40 -42). Thromboembolic risk is generally lower, if less well characterized, than for AF, but is influenced by these relations (40, 41, 43, 44) .
Available guidelines (2, 45, 46) highlight the preeminence of prior stroke in amplifying thromboembolic risk in AF. While the annual risk of thromboembolism is 0.5% in lone AF, it soars to 12% in AF associated with prior [46] .) Although less evidence is available, a similar approach is advocated for atrial flutter (46) , and, in proportion to the likelihood of associated AF, warrants consideration for sick sinus syndrome. LEFT HEART THROMBUS. Since stasis is the principal determinant of left atrial (appendage) thrombus formation, thrombosis in this chamber (Fig. 2 ) is primarily observed with AF or mitral stenosis (48) . Left atrial thrombus also occurs in sinus rhythm when myocardial or valvular disease is present, but is exceedingly rare in their absence (48) . Myocardial infarction and dilated cardiomyopathy are most frequently associated with LV thrombus formation attributable to stasis caused by regional or global myocardial dysfunction (49, 50) . Approximately 1% to 2.5% of patients with acute myocardial infarction will suffer a stroke within 4 weeks, one-half in the first 5 days (51, 52) . Infarct location and severity of systolic dysfunction determine the propensity for thromboembolism (53) . Dyskinetic segments that remodel into aneurysms remain chronic foci for potential thrombosis (54, 55) .
Dilated cardiomyopathy is also associated with LV thrombus. Annual risk of embolization ranges approximately from 1.0% to 3.5% (50, 56) , paralleling the severity of systolic dysfunction (56 -58) , but climbs to 9% once stroke has occurred (59) .
Detection of intracavitary thrombus, especially when mobile, moves the benefit-risk calculus in favor of early post-stroke anticoagulation. In sinus rhythm, anticoagulation should be instituted for at least 3 months, unless contraindicated, with demonstration of thrombus resolution by echocardiography (1, 60) . Absent detectable thrombus, opinion is divided regarding anticoagulation for secondary stroke prevention in acute myocardial infarction or dilated cardiomyopathy (1, 61) , but it is recommended for rheumatic mitral stenosis (1, 62, 63) . CARDIAC TUMORS. Primary cardiac tumors are rare, accounting for a small minority of cerebrovascular events in reported series (21) . Detachment of tumor fragments or superimposed thrombi underlies embolic risk (64) . Myxoma is the most common, exceeding 50% of all benign cardiac tumors (64), while papillary fibroelastoma accounts for another 30% (65) . Secondary stroke prevention entails surgical resection of myxoma or large, mobile fibroelastomas (2, 64, 65) . This is usually definitive, but myxoma recurrences can occur (64). VALVULAR VEGETATIONS. The incidence of ischemic stroke associated with infective endocarditis is 15% to 20% (66) , with the highest risk in the first 7 to 10 days after presentation. Mitral valve involvement carries greater stroke risk than aortic valve involvement (67) . Embolic risk is also increased by mobility, consistency, extent, and size (67) (68) (69) . Marantic endocarditis, characterized by noninfective valvular vegetations, is seen in neoplastic or other debilitating disorders and also confers a high risk of embolism (69, 70) .
Treatment must be directed at the underlying cause. Infective endocarditis requires administration of systemic antibiotics and, if indicated, surgery (66) . Noninfective endocarditis is treated with tumor-suppressive, antiretroviral, or immunosuppressive therapy with systemic anticoagulation, preferably heparin based (62), as appropriate. Sterile vegetations, especially when large and mobile, make immediate post-stroke anticoagulation compelling unless hemorrhagic risk is excessive. PROSTHETIC VALVES. Systemic embolization occurs as a complication of both bioprosthetic and mechanical heart valves at 1% to 4% annually (62) . Eighty percent of clinical thromboemboli associated with prosthetic valves involve the brain. The absolute yearly risk of cerebral embolism is higher for prosthetic valves in the mitral (2% to 3.5%) than aortic position (1% to 2%), and this risk is amplified by AF (62). 
High-intensity anticoagulation (INR 2.5 to 3.5) is recommended for modern mechanical prostheses when cerebral ischemia occurs, with addition of low-dose aspirin when the event occurs despite a therapeutic INR (1, 62) . Moderate-intensity anticoagulation can be considered in the case of bioprostheses (1, 62) . Early initiation/intensification of antithrombotic therapy should be entertained. CAA. Various studies in populations with cerebral ischemia have established a link between protruding aortic atheroma and systemic embolism (71) , although an independent relation was not demonstrated in a communitybased study with a modest number of outcomes (72) . In a prospective investigation of stroke patients age Ͼ60 years, the presence of proximal aortic atheroma Ն4 mm in thickness conferred a recurrence risk of 11.9 per 100 person-years, compared with 3.5 per 100 person-years or less observed for atheroma Ͻ4.0 mm (73) . A TEE substudy in AF, which defined CAA as Ն4 mm or containing ulceration or mobile components (23), demonstrated a 4-fold greater risk of thromboembolism with than without CAA. Taken together, available data in patients with cerebral ischemia or AF show CAA to heighten thromboembolic risk, either directly or through associated cardiovascular disease (71) .
Although CAA-associated thrombi would be expected to be platelet-rich, some small-scale observational data suggest that secondary prevention with anticoagulation may be superior to antiplatelet therapy (71) . Still, current guidelines do not recommend routine anticoagulation (2) . In the presence of mobile atheroma, however, early systemic anticoagulation can be considered (Table 3) (2, 62) . The best antithrombotic strategy awaits completion of clinical trials, but aggressive lipid lowering and renin-angiotensin antagonism are indicated (74) .
Medium-or Uncertain-Risk Sources
PFO. This fetal remnant constitutes a potential conduit for right-to-left shunting in 25% to 30% of adults (36) . Many (75) , but not all (76, 77) , studies have documented an association between PFO and ischemic stroke, particularly in adults Յ55 years of age, in whom the prevalence rises to 50%. This relation is stronger for cryptogenic stroke, suggesting that PFO may be important in the pathogenesis of cerebral infarction. The putative mechanism, based on rare instances of thrombus "in transit" across the foramen in patients with stroke (Fig. 3) , is paradoxical embolism (78) . Joint occurrence of venous thromboembolism and PFO suffices for a circumstantial diagnosis of paradoxical embolism (78) , and autopsy series have identified paradoxical embolism as the culprit in as many as 4% of brain infarcts in this manner (79) . In such reports, however, cases with major pulmonary embolism have predominated, leading to ascertainment bias. By contrast, antemortem stroke studies seldom uncover clinically overt pulmonary embolism or sonographic deep-vein thrombosis (36) . This has prompted consideration of alternative mechanisms for the PFO-stroke association, including in situ thrombosis and atrial dysrhythmias, but these are also rarely documented (36) . Nevertheless, a 1-mm thrombus sufficient to produce a clinical stroke can well elude detection by existing venous imaging modalities. Moreover, more extensive evaluation with conventional venography (80) and MRI venography (81) has documented frequent calf-vein and pelvic-vein thrombosis in patients with unexplained systemic embolism and interatrial shunts.
Population estimates suggest that PFOs generally have low pathogenicity (36) . Additional factors must, therefore, act to increase thromboembolic risk. Intrinsic PFO features such as anatomical degree of patency (82) , magnitude of microbubble passage (83) , septum-primum hypermobility (84) , or presence of atrial septal aneurysm (ASA) (85) have been reported to amplify risk. Moreover, an individual's propensity to venous thrombosis, either from immobility or hypercoagulable state, influences the associated risk of paradoxical embolism (78) . ASA. Defined as exaggerated excursion of the septum into the atrial chambers, ASA occurs more frequently in patients (86) . The precise mechanism underlying this association is unclear. An interatrial shunt is present in 50% to 90% of ASAs, suggesting paradoxical embolism as the pathophysiological basis (36) . Additional potential mechanisms include in situ thrombosis (87) and associated atrial dysrhythmias (88) . PFO and ASA. There is no consensus regarding optimal secondary stroke prevention for PFO (36) . Treatment options include antiplatelet or anticoagulant agents, and percutaneous or surgical closure. A substudy of patients with noncardioembolic stroke randomized to aspirin versus warfarin who underwent TEE found no difference in recurrent stroke or death, irrespective of PFO size or presence of ASA (89) . In a subgroup with cryptogenic stroke, however, warfarin reduced by one-half the risk of stroke or death, but this analysis was underpowered (89) . In a separate study of younger patients with cryptogenic stroke receiving aspirin, prospective follow-up showed a similar 4-year risk of stroke recurrence for patients with isolated PFO and without PFO (85) . For patients with both PFO and ASA, however, the risk of recurrence was 4-fold greater than without either abnormality (85) . (Larger shunt size was associated with ASA, but it did not influence the risk of stroke recurrence.) This observation, though at variance with findings in older adults (89) , suggests that aspirin affords insufficient protection for young cryptogenic stroke patients with combined PFO and ASA. Patent foramen ovale closure has been traditionally accomplished by open thoracotomy, but percutaneous closure represents an attractive alternative (36) . Nevertheless, there are no available randomized data on the relative merits of percutaneous (or surgical) closure and medical therapy (36) . Clinical trials addressing this question are ongoing.
Current guidelines conclude that available evidence precludes definitive treatment recommendations (1, 2, 36) . Given the high population prevalence of PFO, in the absence of high-risk clinical findings or septal characteristics, it is difficult to establish the pathogenetic significance or risk of PFO in the individual stroke patient. Accordingly, antiplatelet therapy is favored for PFO unless concurrent venous thromboembolism or hypercoagulable state requiring anticoagulation is detected (1,2) . In the setting of cryptogenic stroke and PFO with high-risk features-large shunt (Ͼ50 bubbles), ASA, antecedent Valsalva, multiple infarcts-especially in younger adults, long-term anticoagulation may be a preferred strategy. This is in keeping with the fibrin-rich composition of venous-source thrombi (36) . Patients interested in percutaneous closure should be encouraged to participate in clinical trials. Surgical closure is an alternative when anticoagulation is contraindicated. Optimal secondary prevention for isolated ASA remains uncertain. Intrapulmonary shunt. Pulmonary arteriovenous malformations, which constitute a conduit for paradoxical embolization, can be isolated or associated with liver disease or hereditary hemorrhagic telangiectasia (90) . Among referrals for endovascular occlusion, cerebral infarction was documented in 32% of patients with single, and 60% with multiple, malformations (91) .
Transcatheter embolotherapy is favored for secondary stroke prevention for malformations Ն3 mm in diameter (91) . Spontaneous echo contrast ("smoke"). This swirling cloud visible within cardiac chambers by echocardiography reflects rouleaux formation from low flow, increased fibrinogen, or high hematocrit (92) . Hence, it is common in disorders such as AF and mitral stenosis, as well as prosthetic heart valves and severe ventricular dysfunction.
In AF, smoke typically occurs in the left atrial appendage, where it correlates with reduced contractility (93) . Dense smoke in the appendage is not only associated with thrombus, but also predicts incidence of AF-related thromboembolism (23) .
Because dense smoke represents a pre-thrombotic condition and is a marker of thromboembolic risk in AF, mitral stenosis, or valvular replacement (94) , systemic anticoagulation may be contemplated in cryptogenic stroke patients in sinus rhythm with this finding. Mitral valve prolapse. Early studies reported an association between mitral valve prolapse and stroke, especially in patients Ͻ45 years of age (95) . Such studies applied echocardiographic criteria that did not take into account the saddle-like shape of the mitral annulus. Subsequent revision of these criteria yielded greater specificity, and several studies, albeit of limited power, have since failed to document an association (96, 97) .
Guidelines do not recommend post-stroke anticoagulation (1,2,63), except when leaflet thickening or mitral regurgitation is present (63) (Table 3) . Valvular calcification. Mitral annular calcification and aortic valve sclerosis are associated with atherosclerotic vascular disease (98, 99) . Prospective studies have shown mitral annular calcification to increase the risk of stroke (100), but the same has been documented for aortic valve sclerosis only when stenosis is present (101) . While the association of mitral annular calcification with stroke reflects its status as a marker for atherosclerotic disease, several reports attest to mitral annular calcification's potential as a direct source of calcific or thrombotic debris (98) .
Recognizing the scant available data, published guidelines (1,62) suggest different general approaches to cerebral embolism not documented to be calcific in association with mitral annular calcification (Table 3) , but urge consideration of anticoagulation for accompanying mitral valve disease. Valvular strands. These mobile filaments represent endothelialized fibrin deposits arising from microabrasions of valvular endothelium (102) . Associations between valvular excrescences and stroke, ostensibly from embolization, have been reported in cross-sectional studies (102), but failure of longitudinal studies to replicate the findings (103-105) makes a causal association suspect.
